COMMUNIQUÉS West-GlobeNewswire

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
06/05/2026
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies CHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, [...]
MedWell Ai, Inc Reports Q3 Revenues Of $618,676 And Provides Corporate Update
06/05/2026
CLEARWATER, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- MedWell Ai, Inc, (OTCQB:MWAI) ("Company") is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and [...]
Jito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region
06/05/2026
Pairing Jito's market layer technology and Solana Company's institutional Pacific Backbone platform intended to advance validator infrastructure and staking solutions across Asia-Pacific MIAMI, May 06, 2026 (GLOBE [...]
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
06/05/2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
06/05/2026
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achieved $21.7 million in [...]
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
06/05/2026
MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
06/05/2026
Final results confirm and build on interim BIRCH results in 23 ICH patients Primary safety endpoint met with no mortality observed Encouraging efficacy signals on all clinical and biomarker endpoints New adaptive [...]
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
06/05/2026
Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “ [...]
Better Blend Continues Growth with Second Lexington Location
06/05/2026
Fast-growing Midwest brand brings low-sugar, high-protein menu to the area LEXINGTON, Ky., May 06, 2026 (GLOBE NEWSWIRE) -- Better Blend, a rapidly growing smoothie and bowl brand, opened its second location in [...]
Brain Cancer Canada Awards $75,000 to Groundbreaking Pediatric Brain Cancer Study at University of Manitoba Targeting Hard-to-Treat DMG-P Tumours
06/05/2026
TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada, the country’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide, is proud to award $75,000 to first-of- [...]
SeaStar Medical to Report First Quarter Financial Results on May 13, 2026
06/05/2026
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
06/05/2026
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - [...]
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
06/05/2026
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its [...]
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
06/05/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed [...]
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
06/05/2026
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™ ) planned for the second quarter of 2026 Initiation [...]
Immunocore reports first quarter financial results and provides a business update
06/05/2026
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles [...]
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront [...]
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
06/05/2026
200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a [...]
Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary
06/05/2026
Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances towards first-in-human studies Cambridge, UK, 6 th May 2026 Immutrin Ltd, (“Immutrin” [...]

Pages